Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
Portfolio Pulse from
Myriad Genetics (MYGN) reported Q3 earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of $0.02 per share, and improved from a loss of $0.03 per share a year ago.
November 08, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics reported Q3 earnings of $0.06 per share, exceeding expectations and showing improvement from last year's loss.
The earnings report shows a positive surprise with earnings per share exceeding estimates and a significant improvement from the previous year's loss. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100